All questions are shown as received by the Trust.
1. Please complete the table below with how many newly diagnosed patients with AML have started first-line treatment with each of the following therapies during the 6-month period February 2024 to July 2024?
• Azacitidine monotherapy
• Low dose cytarabine (LoDAC) monotherapy
• Venetoclax + azacitidine
• Venetoclax + LoDAC
• Ivosidenib
• Intensive chemotherapy-based regimen
O Examples include: cytarabine and daunorubicin, idarubicin, fludarabine, mitoxantrone, etoposide (VP-16), 6-thioguanine (6-TG), methotrexate (MTX) or 6-mercaptopurine (6-MP), gemtuzumab ozogamicin with daunorubicin cytarabine, or FLAG-Ida (fludarabine, cytarabine, granulocyte-colony stimulating factor and idarubicin)
• Best supportive care
• Other
O Do not include prophylactic therapies such as GCSF, anti-fungals, antihistamines, anti-nauseants
